Sponsors (4)
The bill boosts U.S.–Israel biomedical collaboration to speed innovation, workforce development, and regulatory coordination, trading modest federal funding and faster access to technologies against risks to data privacy, affordability due to IP priorities, and a concentration of partnership benefits.
Healthcare workers and biomanufacturing staff gain expanded training and exchange programs, increasing skills and supporting U.S. domestic biomanufacturing capacity.
Researchers and biotech companies receive funding and coordinated R&D partnerships with Israeli counterparts, accelerating development of new treatments and diagnostics.
Patients with chronic conditions and hospitals can adopt shared best practices and telemedicine tools, improving care delivery and interoperability.
Patients and health systems face increased privacy and security risks from sharing health data with a foreign government if safeguards and governance are insufficient.
Patients—especially low-income individuals—may face higher costs or reduced access if emphasis on market access and strong IP protections favors private firms and commercialization over affordability.
Taxpayers fund the program at about $8 million annually from FY2026–2030, increasing federal spending and creating opportunity costs for other priorities.
Based on analysis of 2 sections of legislative text.
Authorizes a federal HHS-led program (plus possible U.S. center) to coordinate U.S.–Israel medical technology collaboration and authorizes $8M/year for FY2026–2030, subject to appropriations.
Creates a U.S. program to coordinate and support bilateral collaboration with Israel on developing and delivering health care products and services, including joint research, startup and innovation support, regulatory alignment, intellectual property protection, telemedicine cooperation, workforce training, and biological product manufacturing. The Health and Human Services Secretary, consulting Commerce, CMS innovation council, and FDA, may establish a U.S.–Israel Health Care Collaboration Center and must begin implementation within six months. The measure authorizes $8 million per year for FY2026–FY2030, subject to available appropriations.
Official title: To require the Secretary of Health and Human Services, in consultation with the Secretary of Commerce, the Council for Technology and Innovation of the Centers for Medicare & Medicaid Services, and the Commissioner of Food and Drugs, to carry out a program to facilitate and coordinate efforts between the United States and Israel to expand and enhance collaboration on the development and delivery of health care products and services.
Introduced January 23, 2025 by Vernon G. Buchanan · Last progress January 23, 2025